Clinical and Experimental Vaccine Research

  • 제11권2호
  • /
  • Pages.149-154
  • /
  • 2022
  • /
  • 2287-3651(pISSN)
  • /
  • 2287-366X(eISSN)
대한백신학회 (The Korean Vaccine Society)
권호 표지
DOI QR코드

DOI QR Code

A survey of healthcare workers' recommendations about human papillomavirus vaccination

  • 투고 : 2022.03.07
  • 심사 : 2022.05.06
  • 발행 : 2022.05.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: The human papillomavirus (HPV) vaccine is safe and effective for preventing HPV-related diseases. However, HPV vaccination rates in Japan are low because the "Ministry of Health, Labour and Welfare" had stopped recommending vaccination. We assessed healthcare workers' (HCWs) current recommendations regarding the HPV vaccine and how the provision of information about HPV vaccination affected their recommendations. Materials and Methods: A survey was conducted among nurses and physicians in Nara prefecture from March 2021 to July 2021. The questionnaire asked about their understanding, recommendations, and opinions regarding HPV vaccination. Before answering the last two questions (optional), the HCWs read evidence-based information quantifying the risks and benefits of HPV vaccination. Results: A total of 441 HCWs completed the questionnaire. Only 19% of HCWs always recommended HPV vaccination for girls aged 12-16 years. The evidence-based information significantly improved the percentage of HCWs who would "always recommend" vaccination. Conclusion: This study showed that the proportion of HCWs who recommend HPV vaccination to adolescent girls remains low in Japan. However, we found that evidence-based information describing the causal relationship between adverse events and vaccination, quantifying the risks and benefits, noting the importance of HCW communications with families, and reporting the recommendations of national societies, might increase HCWs' recommendations for HPV vaccination.

키워드

과제정보

We gratefully acknowledge Tomoko Hashiguchi (Department of Nursing, Nara Medical University) who efforted to disseminate our research, and we also acknowledge all healthcare workers who kindly participated in this study.

참고문헌

  1. Lei J, Ploner A, Elfstrom KM, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med 2020;383:1340-8.
  2. Suzuki S, Hosono A. No association between HPV vaccine and reported post-vaccination symptoms in Japanese young women: results of the Nagoya study. Papillomavirus Res 2018;5:96-103.
  3. Simms KT, Hanley SJ, Smith MA, Keane A, Canfell K. Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study. Lancet Public Health 2020;5:e223-34.
  4. Larson HJ. Japan's HPV vaccine crisis: act now to avert cervical cancer cases and deaths. Lancet Public Health 2020;5:e184-5.
  5. Mizumachi K, Aoki H, Kitano T, Onishi T, Takeyama M, Shima M. How to recover lost vaccine acceptance?: a multicenter survey on HPV vaccine acceptance in Japan. J Infect Chemother 2021;27:445-9.
  6. Sawada M, Ueda Y, Yagi A, et al. HPV vaccination in Japan: results of a 3-year follow-up survey of obstetricians and gynecologists regarding their opinions toward the vaccine. Int J Clin Oncol 2018;23:121-5.
  7. Katsuta T, Moser CA, Offit PA, Feemster KA. Japanese physicians' attitudes and intentions regarding human papillomavirus vaccine compared with other adolescent vaccines. Papillomavirus Res 2019;7:193-200.
  8. Ministry of Health, Labour and Welfare. Human papillomavirus infection, cervical cancer and HPV vaccine, for healthcare workers [Internet]. Tokyo: Ministry of Health, Labour and Welfare; [date unknown] [cited 2021 May 19]. Available from: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou/kekkaku-kansenshou19/leaflet.html.
  9. Nara Medical University, Department of Pediatrics. HPV vaccine [Internet]. Kashihara: Nara Medical University; 2021 [cited 2021 May 19]. Available from: https://www.naramed-u.ac.jp/~ped/pdf/cervical_cancer_vaccine.pdf.
  10. Kitano T. Stopping the HPV vaccine crisis in Japan: quantifying the benefits and risks of HPV vaccination in quality-adjusted life-years for appropriate decision-making. J Infect Chemother 2020;26:225-30.
  11. Arbyn M, Xu L. Efficacy and safety of prophylactic HPV vaccines: a Cochrane review of randomized trials. Expert Rev Vaccines 2018;17:1085-91.
  12. Van Damme P, Olsson SE, Block S, et al. Immunogenicity and safety of a 9-valent HPV vaccine. Pediatrics 2015;136:e28-39.
  13. European Centre for Disease Prevention and Control. Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction [Internet]. Stockholm: ECDC; 2020 [cited 2021 May 19]. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Guidance-on-HPV-vaccination-in-EU-countries2020-03-30.pdf.
  14. Mikamo H, Yamagishi Y, Murata S, et al. Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: a randomized, phase 3, placebo-controlled study. Vaccine 2019;37:1651-8.
  15. Ng SS, Hutubessy R, Chaiyakunapruk N. Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-valent vaccine, gender-neutral and multiple age cohort vaccination. Vaccine 2018;36:2529-44.